CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 161 enrolled
Drug / intervention
EYP-1901 +1 moredrug
Likely dose
Aflibercept 2mg/0.05mL Inj,Ophfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05381948
NCT05381948Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD

EyePoint Pharmaceuticals, Inc.·interventional·Posted May 19, 2022·Updated Oct 15, 2025

In Brief

A Phase 2 clinical trial evaluating EYP-1901 and Aflibercept 2mg/0.05mL Inj,Oph for Wet Age-related Macular Degeneration. Completed, enrolled 161 participants across 67 sites.

Detailed Summary

This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWet Age-related Macular Degeneration
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedMay 19, 2022
Enrollment StartJun 30, 2022
Primary CompletionNov 29, 2023
Study CompletionApr 24, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.1 years ago

Interventions

EYP-1901drug

Intravitreal Injection

Aflibercept 2mg/0.05mL Inj,Ophdrug

Intravitreal Injection